HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

HUTCHMED (China) LimitedNASDAQ: HCM

Stock-Based Compensation · Q2 FY2025 · quarter ended Jun 2025

Stock-based compensation declines year over year

Q2 FY2025 stock-based compensation of $3.85M fell 32.0% year over year, ahead of the -47.3% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -20.6% a year.

Context

  • Stock-based compensation amounted to 2.8% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -32.0% holds above the trailing-twelve-month pace of -47.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2025
$3.85M+0.0% QoQ
Last fiscal yearDec 2025
$15.29M-29.2% YoY
LTMJun 2025
$17.99M-47.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.0%——
1 year-29.2%——
3-year CAGR-20.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
15.29M USD
Year-over-year change
-29.2%
4-year CAGR
-22.3%

Stock-Based Compensation vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -47.3% is the 7th highest of 8, against a peer median of -6.0%.
  • Stock-based compensation amounts to 3.0% of revenue for HCM, versus a peer median of 4.2%.
HCM Competitors
Stock-Based Compensation for HCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$187.88M USD-31.7%+9.8%3.2%
EXELExelixis, Inc.LTM Jul 2026$112.6M USD+1.1%+1.6%4.6%
GMABGenmab A/SLTM Jun 2026$71M USD——1.7%
RCUSArcus Biosciences, Inc.LTM Jun 2026$63M USD-6.0%-2.6%53.8%
ZLABZai Lab LimitedLTM Jun 2026$58.29M USD-12.7%+2.3%13.0%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$50.41M USD+30.4%+58.3%22.4%
AAPGAscentage Pharma Group InternationalFY2025CN¥20.87M CNY-0.2%-1.9%3.7%
HCMHUTCHMED (China) LimitedLTM Jun 2025$17.99M USD-47.3%-20.6%3.0%
LEGNLegend Biotech CorporationLTM Sep 2026$7.7M USD-87.8%—0.6%
ANLAdlai Nortye Ltd.LTM Jun 2024$1.94M USD——29.9%
BNTXBioNTech SELTM Jun 2026€0 EUR——0.0%
Peer median (excluding HCM) —-6.0%+2.0%4.2%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(167.04M)(360.39M)100.78M37.73M458.12M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
Deferred Income Tax(115.14M)0(102.76M)00
Stock-Based Compensation41.99M30.59M36.6M21.61M15.29M
Change in Working Capital32.46M58.7M71.15M(62.17M)(61.02M)
Accounts Receivables(35.63M)(14.45M)(21.34M)(41.57M)28.94M
Inventory(16M)(21.21M)4.14M(772K)9.57M
Accounts Payables9.57M29.94M(32.54M)03.02M
Other Working Capital74.53M64.04M120.89M(19.82M)(102.55M)
Other Non-Cash Items(3.68M)(6.17M)105.28M(9.01M)(490.56M)
Operating Cash Flow(204.22M)(268.6M)219.26M497K(64.83M)
Capital Expenditures(16.76M)(36.66M)(32.61M)(17.93M)(14.19M)
Acquisitions (Net)159.12M324K(2.99M)028.07K
Purchases of Investments(1.37B)(1.2B)(1.63B)(1.85B)(2.75B)
Sales of Investments921.36M1.52B1.37B1.77B2.74B
Other Investing Activities930K16.49M29.5M1.28M0
Investing Cash Flow(306.32M)296.59M(291.14M)(96.06M)(29.49M)
Debt Repayment(579.77K)(9.17M)61.71M5.61M6.27M
Common Stock Issued717.32M174K5.09M790K1.58M
Common Stock Repurchased(27.31M)(48.08M)(9.07M)(36.06M)0
Dividends Paid(99.74M)(87.44M)000
Other Financing Activities60.34M61.75M(9.07M)(1M)0
Financing Cash Flow650.03M(82.76M)48.66M(30.67M)7.86M
Effect of Forex Changes2.43M(9.49M)(6.47M)(3.4M)3.83M
Net Change in Cash141.91M(64.26M)(29.69M)(129.63M)(82.63M)
Free Cash Flow(220.98M)(305.26M)186.65M(17.44M)(79.01M)

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.